Dr. Rosén is an accomplished life sciences executive and physician with nearly three decades of experience that includes directing biologic clinical research and development and building, leading and successfully launching multiple novel medicines in the United States and globally.
Prior to Horizon, she was senior vice president, US medical affairs at GlaxoSmithKline (NYSE: GSK), where she led a team of more than 300 physicians and medical professionals in disease areas including immunology, respiratory and inflammation.
Prior to GlaxoSmithKline, Dr. Rosén was senior vice president, US and global medical affairs at Aimmune Therapeutics, Inc. as well as a member of the clinical development leadership team working on the Phase 2b-3/4 clinical programs and US FDA and European Medicines Agency filing strategies.
Prior to Aimmune, Dr. Rosén was therapeutic area head, immunology, at Genentech, a member of the Roche Group.
During her tenure at Genentech, she also served as lead medical director responsible for developing Phase 2-3 clinical programs for multiple biologics in the areas of immunology, respiratory, allergy and dermatology.
Dr. Rosén received her medical degree and doctorate from Lund University in Lund, Sweden.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary